Clinical trials: Cmv Congenital, open to volunteers
Pregnant Women, CMV Infected Fetuses
Prenatal Treatment of Congenital Cytomegalovirus Infection With Letermovir Versus Valaciclovir
The investigators' hypothesis is that maternal treatment with Letermovir will inhibit fetal CMV replication better than Valaciclovir in infected fetuses and lead to a higher proportion of negative CMV PCR at birth in neonatal…
- Trial name
- CYMEVAL3-step2 (NCT05446571)
- Testing
- Letermovir, Valacyclovir
- Where
- France
- Volunteers
- 46 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Congenital Cytomegaloviral (CMV) Disease
CMV CTLs in Neonates With CMV Infection
Patients with moderate or severe CMV disease less than 21 days old who have a maternal donor who has a CMV response to the peptivators will be screened. All patients will receive treatment with valganciclovir or ganciclovir.
- Trial name
- NCT05564598
- Testing
- CMV Cytotoxic T-Lymphocytes, Anti-viral Therapy
- Where
- 4 sites in United States
- Volunteers
- 23 people
- Sponsor
- New York Medical College
Cytomegalovirus Infections
Ganciclovir Resistant/Refractory Cytomegalovirus Infection in SOT Recipients and HSCT Patients
The ReCySOHT study is a multicenter, retrospective, observational case-control study on the risk factors for developing a ganciclovir-resistant/refractory (GCV-RR) cytomegalovirus infection in patients receiving solid organ…
- Trial name
- ReCySOHT (NCT05234723)
- Where
- 23 sites in United States, Belgium and 7 more
- Volunteers
- 100 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Congenital CMV Infection, Sensorineural Hearing Loss
Long-Term Outcomes of Children With Congenital CMV in New York State
PROACTIVE NYS is a long-term follow-up study of all infants who test positive for congenital Cytomegalovirus infection (CMV) throughout New York State on the Newborn Screen.
- Trial name
- PROACTIVE NYS (NCT06226558)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Stony Brook University
Congenital Cytomegalovirus, Cytomegalovirus Infections
Protein Biomarkers and Host RNA Expression Profiles in Congenital Cytomegalovirus Infection
This study seeks to identify and test host protein biomarkers and RNA expression profiles in dried blood spot samples as novel diagnostic markers of congenital cytomegalovirus sequelae and to improve the understanding of the…
- Conditions
- Congenital Cytomegalovirus, Cytomegalovirus Infections, Neonatal Infection, Sensorineural Hearing Loss
- Trial name
- NCT07635368
- Where
- 2 sites in Denmark
- Volunteers
- 630 people, healthy volunteers welcome
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Congenital Cmv
Observational Study of the Management of Infants With Congenital CMV
This is an observational, prospective/retrospective multicentre, cohort study of children diagnosed with cCMV. This study will contribute to a wider study also recruiting participants in Europe and other countries worldwide.
- Trial name
- cCMVnet (NCT05855889)
- Where
- United Kingdom
- Volunteers
- 200 people
- Sponsor
- St George's, University of London
Congenital CMV Infection
Evaluation of Long-term Efficacy of 4 to 6-month Course Antiviral Therapy for Neurodevelopmental Impairments Caused by Congenital Cytomegalovirus Infection
Title: Evaluation of Long-term Efficacy of 4-month versus 6-month Course Antiviral Therapy for Neurodevelopmental Impairment Caused by Congenital CMV Infection: A Multicenter, Randomized, Controlled, Non-inferiority Clinical…
- Trial name
- NCT07450365
- Testing
- Intravenous ganciclovir (6 mg/kg, twice daily) or oral valganciclovir (16 mg/kg, twice daily) was administered for a treatment course of 4 months., Patients received a 6-month course of anti-CMV therapy. The treatment regimen consisted of either intravenous ganciclovir (6 mg/kg, twice daily) or oral valganciclovir (16 mg/kg, twice daily).
- Volunteers
- 150 people
- Sponsor
- Hu Bofei
Cytomegalovirus Infections, Primary Immune Deficiency Disorder
Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)
CMV cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered in children, adolescents and young adults (CAYA) with refractory cytomegalovirus (CMV) infection post…
- Trial name
- NCT03266640
- Testing
- viral specific cytotoxic t-lymphocytes
- Where
- 9 sites in United States
- Volunteers
- 20 people
- Sponsor
- New York Medical College
Sanfilippo Syndrome (MPS III)
Single Injection of rAAV9-CMV-hNAGLUop Gene for Patients With Mucopolysaccharidosis (MPS) IIIB
The goal of this clinical trial is to learn if one infusion of rAAV9-CMV-hNAGLUop can treat patients with Sanfilippo syndrome (MPS III) 6 months or older.
- Trial name
- NCT07818759
- Testing
- rAAV9-CMV-hNAGLUop
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- NeuroGT
EBV Viremia, CMV Viremia
25BT056: Basket Study of Viral Cytotoxic T Lymphocytes
This study is evaluating the safety and effectiveness of virus-specific cytotoxic T lymphocytes (vCTLs) for treating difficult-to-control viral infections caused by cytomegalovirus (CMV), adenovirus (ADV), Epstein-Barr virus…
- Conditions
- EBV Viremia, CMV Viremia, BK Viremia, Adenovirus
- Trial name
- NCT07873970
- Testing
- Virus-Specific Cytotoxic T Lymphocytes (vCTLs)
- Volunteers
- 35 people
- Sponsor
- Children's Hospital of Philadelphia
Human Cytomegalovirus (HCMV)
Immunological and Virological Prognostic Markers of Human Cytomegalovirus (HCMV) Congenital Infection in Pregnant Women With Primary HCMV Infection.
Human cytomegalovirus (HCMV) establishes a lifelong relationship with its host: primary infection is followed by a latency phase with intermittent reactivation episodes, despite a robust, long-lasting immune response.
- Trial name
- NCT07477925
- Where
- Italy
- Volunteers
- 90 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Neonatal Hearing Loss
Overview of Targeted Screening for Congenital Infection Guided by Neonatal Hearing Screening
Cytomegalovirus (CMV) infection is the most common congenital infection. It is the second leading cause of sensorineural hearing loss after genetic causes and the leading cause of motor delay.
- Trial name
- cCMV-DNS (NCT07335874)
- Where
- France
- Volunteers
- 450 people
- Sponsor
- University Hospital, Strasbourg, France
Cytomegalovirus Infections, Maternal Primary Cytomegalovirus Infection
Evaluation of Software for Interpreting Virological Results Indicated for the Diagnosis of Cytomegalovirus (CMV) Infection During Pregnancy and Intended for Health Professionals
Congenital cytomegalovirus (CMV) infection is the most common congenital infection with a birth prevalence of 0.4% in Europe. It is the leading non-genetic cause of sensorineural hearing loss and a major cause of…
- Trial name
- MyCMV (NCT06694428)
- Testing
- Reinterpretation of CMV serology results using the MyCMV tool on the basis of the serology results performed
- Where
- 3 sites in France
- Volunteers
- 491 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris